Skip to content
2000
Volume 2, Issue 1
  • ISSN: 2210-299X
  • E-ISSN: 2210-3007

Abstract

Background

Ovarian cancer is the most fatal gynecological cancer, with the highest death rate because of its late diagnosis and recurrence. Owing to the inherent drawbacks of conventionally available approaches for ovarian cancer treatment, alternative strategies need to be developed. Recently, nanotechnology-based drug delivery vehicles (polymer, liposome, dendrimers, .) have been extensively used in cancer therapy, especially for ovarian cancer. Among various nanoformulations, metal nanoparticle-based approaches are widely studied for ovarian cancer treatment as they offer several advantages, such as high therapeutic output, biocompatibility, non-toxicity, non-inflammatory effects, biodegradability, .

Objective

This review aimed to emphasize the advancement of metal-based nanoformulations for ovarían cancer therapy along with toxicological aspects.

Methods

The information was gathered from many search engines, such as SciFinder, PubMed, and ScienceDirect, to get coverage of suitable research and compile relevant data about metal nanoparticles for ovarian cancer treatment.

Results

Investigating metal nanoparticle-based therapies for the treatment of ovarian cancer provides a new direction for future studies.

Conclusion

This review highlights the anti-cancer activity of metal nanoformulations for ovarian cancer therapy, recent progress, challenges, and future perspectives in detail, along with the toxicological aspects.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cis/10.2174/012210299X310916240801111606
2024-09-10
2025-03-01
The full text of this item is not currently available.

References

  1. Data visualization tools for exploring the global cancer burden in 20222022Available at: https://gco.iarc.fr/today/en
  2. HassanpourS.H. DehghaniM. Review of cancer from perspective of molecular.Fut. J. Pharm. Sci.201744127129
    [Google Scholar]
  3. JassimA. RahrmannE.P. SimonsB.D. GilbertsonR.J. Cancers make their own luck: theories of cancer origins.Nat. Rev. Cancer2023231071072410.1038/s41568‑023‑00602‑537488363
    [Google Scholar]
  4. DingH. ZhangJ. ZhangF. XuY. LiangW. YuY. Nanotechnological approaches for diagnosis and treatment of ovarian cancer: a review of recent trends.Drug Deliv.20222913218323210.1080/10717544.2022.213203236259505
    [Google Scholar]
  5. AroraT. MullangiS. LekkalaM.R. Ovarian Cancer.In StatPearlsTreasure Island (FL)2024
    [Google Scholar]
  6. ÁyenÁ. Jiménez MartínezY. MarchalJ.A. BoulaizH. Recent Progress in Gene Therapy for Ovarian Cancer.Int. J. Mol. Sci.2018197193010.3390/ijms1907193029966369
    [Google Scholar]
  7. BaraniM. BilalM. SabirF. RahdarA. KyzasG.Z. Nanotechnology in ovarian cancer: Diagnosis and treatment.Life Sci.202126611891410.1016/j.lfs.2020.11891433340527
    [Google Scholar]
  8. American cancer society.2022Available from: https://www.cancer.org/research/cancer-facts statistics/all-cancer-facts-figures/cancer-facts-figures2022.html#:~:text=Estimated%20numbers%20of%20new%20cancer,incidence%2C%20mortality%2C%20and%20survival%20statistics
  9. McCluggageW.G. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.Pathology201143542043210.1097/PAT.0b013e328348a6e721716157
    [Google Scholar]
  10. MatulonisU.A. SoodA.K. FallowfieldL. HowittB.E. SehouliJ. KarlanB.Y. Ovarian cancer.Nat. Rev. Dis. Primers2016211606110.1038/nrdp.2016.6127558151
    [Google Scholar]
  11. PuriS. ChadhaV. PandeyA.K. Epidemiology of ovarian tumours in Northern India - A tertiary hospital based study.Indian J. Comm. Family Med.201842374110.4103/2395‑2113.251437
    [Google Scholar]
  12. JessmonP. BoulangerT. ZhouW. PatwardhanP. Epidemiology and treatment patterns of epithelial ovarian cancer.Expert Rev. Anticancer Ther.201717542743710.1080/14737140.2017.129957528277806
    [Google Scholar]
  13. PepaC.D. ToniniG. PisanoC. Di NapoliM. CecereS.C. TambaroR. FacchiniG. PignataS. Ovarian cancer standard of care: are there real alternatives?Chin. J. Cancer2015341172710.5732/cjc.014.1027425556615
    [Google Scholar]
  14. ChandraA. PiusC. NabeelM. NairM. VishwanathaJ.K. AhmadS. BashaR. Ovarian cancer: Current status and strategies for improving therapeutic outcomes.Cancer Med.20198167018703110.1002/cam4.256031560828
    [Google Scholar]
  15. HaqueS. TripathyS. PatraC.R. Graphene-Based Nanomaterials for ROS-Mediated Cancer Therapeutics.Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. ChakrabortiS. SingaporeSpringer Nature Singapore20222891291610.1007/978‑981‑16‑5422‑0_128
    [Google Scholar]
  16. TripathyS. HaqueS. PatraC.R. Metal-based drug delivery systems for cancer immunotherapy.In Advanced and Modern Approaches for Drug DeliveryNayak, A.K., Hasnain, M.S., Laha, B., Maiti, S., EdAcademic Press202385189110.1016/B978‑0‑323‑91668‑4.00014‑9
    [Google Scholar]
  17. LondheS. HaqueS. PatraC.R. Silver and gold nanoparticles: Potential cancer theranostic applications, recent development, challenges, and future perspectives.Gold and Silver Nanoparticles. SahooS. Hormozi-NezhadM.R. Elsevier202324729010.1016/B978‑0‑323‑99454‑5.00006‑8
    [Google Scholar]
  18. RasoolM. MalikA. WaquarS. AroojM. ZahidS. AsifM. ShaheenS. HussainA. UllahH. GanS.H. New challenges in the use of nanomedicine in cancer therapy.Bioengineered202213175977310.1080/21655979.2021.201290734856849
    [Google Scholar]
  19. NirmalaM.J. KizhuveetilU. JohnsonA. GB. NagarajanR. MuthuvijayanV. Cancer nanomedicine: a review of nano-therapeutics and challenges ahead.RSC Advances202313138606862910.1039/D2RA07863E36926304
    [Google Scholar]
  20. DinF. AmanW. UllahI. QureshiO.S. MustaphaO. ShafiqueS. ZebA. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors.Int. J. Nanomedicine2017127291730910.2147/IJN.S14631529042776
    [Google Scholar]
  21. YaoY. ZhouY. LiuL. XuY. ChenQ. WangY. WuS. DengY. ZhangJ. ShaoA. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance.Front. Mol. Biosci.2020719310.3389/fmolb.2020.0019332974385
    [Google Scholar]
  22. BarryN.P.E. SadlerP.J. Challenges for metals in medicine: how nanotechnology may help to shape the future.ACS Nano2013775654565910.1021/nn403220e23837396
    [Google Scholar]
  23. VilleminE. OngY.C. ThomasC.M. GasserG. Polymer encapsulation of ruthenium complexes for biological and medicinal applications.Nat. Rev. Chem.20193426128210.1038/s41570‑019‑0088‑0
    [Google Scholar]
  24. Pitto-BarryA. Polymeric Nanoparticles Containing Ruthenium Complexes for Biomedical Applications: A Mini-Review on Recent Developments.ACS Appl. Polym. Mater.2024acsapm.4c0049410.1021/acsapm.4c00494
    [Google Scholar]
  25. LodhaS. JoshiS. VyasB. KalyankarG. PatelH. DesaiD. Nanotherapeutics for ovarian cancer using metal nanocomposites.Metal Nanocomposites in Nanotherapeutics for Oxidative Stress-Induced Metabolic Disorders.CRC Press2024275302
    [Google Scholar]
  26. KotcherlakotaR. SrinivasanD.J. MukherjeeS. HaroonM.M. DarG.H. VenkatramanU. PatraC.R. GopalV. Engineered fusion protein-loaded gold nanocarriers for targeted co-delivery of doxorubicin and erbB2-siRNA in human epidermal growth factor receptor-2+ ovarian cancer.J. Mater. Chem. B Mater. Biol. Med.20175347082709810.1039/C7TB01587A32263899
    [Google Scholar]
  27. HanC. XieT. WangK. JinS. LiK. DouP. YuN. XuK. Development of fluorescence/MR dual-modal manganese-nitrogen-doped carbon nanosheets as an efficient contrast agent for targeted ovarian carcinoma imaging.J. Nanobiotechnology202018117510.1186/s12951‑020‑00736‑w33256741
    [Google Scholar]
  28. GasparottoG. CostaJ.P.C. CostaP.I. ZagheteM.A. MazonT. Electrochemical immunosensor based on ZnO nanorods-Au nanoparticles nanohybrids for ovarian cancer antigen CA-125 detection.Mater. Sci. Eng. C2017761240124710.1016/j.msec.2017.02.03128482492
    [Google Scholar]
  29. ReidF. The World Ovarian Cancer Coalition Every Woman Study: Identifying challenges and opportunities to improve survival and quality of life.nternational Journal of Gynecological Cancer2020312000983
    [Google Scholar]
  30. PetrucelliN. DalyM.B. PalT. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer.GeneReviews. AdamM.P. FeldmanJ. MirzaaG.M. PagonR.A. WallaceS.E. BeanL.J.H. GrippK.W. AmemiyaA. Seattle, WA1993Vol. R
    [Google Scholar]
  31. Global Ovarian Cancer Drugs Market Report – By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy, Radiation Therapy, and Other Therapies), By Distribution Channel ( Drug Stores and Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast.2023Available from: https://market.us/report/ovarian-cancer-drugs-market/
  32. CortezA.J. TudrejP. KujawaK.A. LisowskaK.M. Advances in ovarian cancer therapy.Cancer Chemother. Pharmacol.2018811173810.1007/s00280‑017‑3501‑829249039
    [Google Scholar]
  33. SinghalS. NieS. WangM.D. Nanotechnology applications in surgical oncology.Annu. Rev. Med.201061135937310.1146/annurev.med.60.052907.09493620059343
    [Google Scholar]
  34. AkterS. RahmanM.A. HasanM.N. AkhterH. NoorP. IslamR. ShinY. RahmanM.D.H. GaziM.S. HudaM.N. NamN.M. ChungJ. HanS. KimB. KangI. HaJ. ChoeW. ChoiT.G. KimS.S. Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements.Cells202211465010.3390/cells1104065035203301
    [Google Scholar]
  35. ZhaoN. YanL. ZhaoX. ChenX. LiA. ZhengD. ZhouX. DaiX. XuF.J. Versatile Types of Organic/Inorganic Nanohybrids: From Strategic Design to Biomedical Applications.Chem. Rev.201911931666176210.1021/acs.chemrev.8b0040130592420
    [Google Scholar]
  36. RaoG.G. MillerD.S. Hormonal therapy in epithelial ovarian cancer.Expert Rev. Anticancer Ther.200661434710.1586/14737140.6.1.4316375643
    [Google Scholar]
  37. RiggsM.J. PandalaiP.K. KimJ. DietrichC.S. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.Diagnostics20201014310.3390/diagnostics1001004331947647
    [Google Scholar]
  38. GuyonL. AscencioM. CollinetP. MordonS. Photodiagnosis and photodynamic therapy of peritoneal metastasis of ovarian cancer.Photodiagn. Photodyn. Ther.201291163110.1016/j.pdpdt.2011.08.00322369725
    [Google Scholar]
  39. YangC. XiaB.R. ZhangZ.C. ZhangY.J. LouG. JinW.L. Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.Front. Immunol.20201157786910.3389/fimmu.2020.57786933123161
    [Google Scholar]
  40. TohmeS. SimmonsR.L. TsungA. Surgery for Cancer: A Trigger for Metastases.Cancer Res.20177771548155210.1158/0008‑5472.CAN‑16‑153628330928
    [Google Scholar]
  41. Perez-FidalgoJ.A. GrauF. FariñasL. OakninA. Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine.Crit. Rev. Oncol. Hematol.202115810320910.1016/j.critrevonc.2020.10320933388455
    [Google Scholar]
  42. ThomasG.M. DemboA.J. Integrating radiation therapy into the management of ovarian cancer.Cancer199371S4Suppl.1710171810.1002/cncr.28207104418431909
    [Google Scholar]
  43. WuQ. YangZ. NieY. ShiY. FanD. Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches.Cancer Lett.2014347215916610.1016/j.canlet.2014.03.01324657660
    [Google Scholar]
  44. YanL. ShenJ. WangJ. YangX. DongS. LuS. Nanoparticle-Based Drug Delivery System: A Patient-Friendly Chemotherapy for Oncology.Dose Response202018310.1177/155932582093616132699536
    [Google Scholar]
  45. LabhasetwarV. Leslie-PeleckyD.L. Biomedical applications of nanotechnology.Biophys Rev201792798910.1002/9780470152928
    [Google Scholar]
  46. NikolovaM.P. ChavaliM.S. Metal Oxide Nanoparticles as Biomedical Materials.Biomimetics2020522710.3390/biomimetics502002732521669
    [Google Scholar]
  47. TutejaJ. VyasA. SandA. Utility of nanomedicine and nanocarriers for noninfectious disease treatment.Nanotechnology for Drug Delivery and Pharmaceuticals.Elsevier202320722310.1016/B978‑0‑323‑95325‑2.00014‑6
    [Google Scholar]
  48. ChandaranaM. CurtisA. HoskinsC. The use of nanotechnology in cardiovascular disease.Appl. Nanosci.2018871607161910.1007/s13204‑018‑0856‑z
    [Google Scholar]
  49. SimosY.V. SpyrouK. PatilaM. KaroutaN. StamatisH. GournisD. DounousiE. PeschosD. Trends of nanotechnology in type 2 diabetes mellitus treatment.Asian Journal of Pharmaceutical Sciences2021161627610.1016/j.ajps.2020.05.00133613730
    [Google Scholar]
  50. NazemA. MansooriG.A. Nanotechnology for Alzheimer’s disease detection and treatment.Insciences J.20111416919310.5640/insc.0104169
    [Google Scholar]
  51. WangX. YangL. ChenZ. ShinD.M. Application of nanotechnology in cancer therapy and imaging.CA Cancer J. Clin.20085829711010.3322/CA.2007.000318227410
    [Google Scholar]
  52. JinC. WangK. Oppong-GyebiA. HuJ. Application of Nanotechnology in Cancer Diagnosis and Therapy - A Mini-Review.Int. J. Med. Sci.202017182964297310.7150/ijms.4980133173417
    [Google Scholar]
  53. BriggerI. DubernetC. CouvreurP. Nanoparticles in cancer therapy and diagnosis.Adv. Drug Deliv. Rev.201264243610.1016/j.addr.2012.09.00612204596
    [Google Scholar]
  54. BlancoE. KessingerC.W. SumerB.D. GaoJ. Multifunctional micellar nanomedicine for cancer therapy.Exp. Biol. Med. (Maywood)2009234212313110.3181/0808‑MR‑25019064945
    [Google Scholar]
  55. YuX. TraseI. RenM. DuvalK. GuoX. ChenZ. Design of Nanoparticle-Based Carriers for Targeted Drug Delivery.J Nanomater2016108725010.1155/2016/1087250
    [Google Scholar]
  56. MalamY. LoizidouM. SeifalianA.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.Trends Pharmacol. Sci.2009301159259910.1016/j.tips.2009.08.00419837467
    [Google Scholar]
  57. KriegerM.L. EcksteinN. SchneiderV. KochM. RoyerH.D. JaehdeU. BendasG. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro.Int. J. Pharm.20103891-2101710.1016/j.ijpharm.2009.12.06120060458
    [Google Scholar]
  58. FengS.T. LiJ. LuoY. YinT. CaiH. WangY. DongZ. ShuaiX. LiZ.P. pH-sensitive nanomicelles for controlled and efficient drug delivery to human colorectal carcinoma LoVo cells.PLoS One201496e10073210.1371/journal.pone.010073224964012
    [Google Scholar]
  59. JanaszewskaA. LazniewskaJ. TrzepińskiP. MarcinkowskaM. Klajnert-MaculewiczB. Cytotoxicity of Dendrimers.Biomolecules20199833010.3390/biom908033031374911
    [Google Scholar]
  60. SharmaA.K. GothwalA. KesharwaniP. AlsaabH. IyerA.K. GuptaU. Dendrimer nanoarchitectures for cancer diagnosis and anticancer drug delivery.Drug Discov. Today201722231432610.1016/j.drudis.2016.09.01327671487
    [Google Scholar]
  61. ZhangC. PanD. LuoK. LiN. GuoC. ZhengX. GuZ. Dendrimer–doxorubicin conjugate as enzyme-sensitive and polymeric nanoscale drug delivery vehicle for ovarian cancer therapy.Polym. Chem.20145185227523510.1039/C4PY00601A
    [Google Scholar]
  62. DengS. GigliobiancoM.R. CensiR. Di MartinoP. Polymeric Nanocapsules as Nanotechnological Alternative for Drug Delivery System: Current Status, Challenges and Opportunities.Nanomaterials202010584710.3390/nano1005084732354008
    [Google Scholar]
  63. KothamasuP. KanumurH. RavurN. MadduC. ParasuramrajamR. ThangavelS. Nanocapsules: the weapons for novel drug delivery systems.Bioimpacts201222718123678444
    [Google Scholar]
  64. AkandaM. MithuM.D.S.H. DouroumisD. Solid lipid nanoparticles: An effective lipid-based technology for cancer treatment.J. Drug Deliv. Sci. Technol.20238610470910.1016/j.jddst.2023.104709
    [Google Scholar]
  65. NigamP. GidwaniB. GuptaA. KaurC.D. Solid lipid nanoparticles a tool combating Ovarian Cancer.J. Pharm. Biol Sci.201645160
    [Google Scholar]
  66. MitchellM.J. BillingsleyM.M. HaleyR.M. WechslerM.E. PeppasN.A. LangerR. Engineering precision nanoparticles for drug delivery.Nat. Rev. Drug Discov.202120210112410.1038/s41573‑020‑0090‑833277608
    [Google Scholar]
  67. JagaranK. SinghM. Nanomedicine for neurodegenerative disorders: Focus on Alzheimer’s and Parkinson’s diseases.Int. J. Mol. Sci.20212216908210.3390/ijms2216908234445784
    [Google Scholar]
  68. MaheriH. HashemzadehF. ShakibapourN. KamelniyaE. Malaekeh-NikoueiB. MokaberiP. ChamaniJ. Glucokinase activity enhancement by cellulose nanocrystals isolated from jujube seed: A novel perspective for type II diabetes mellitus treatment (In vitro).J. Mol. Struct.2022126913380310.1016/j.molstruc.2022.133803
    [Google Scholar]
  69. KalhoriF. YazdyaniH. KhademorezaeianF. HamzkanlooN. MokaberiP. HosseiniS. ChamaniJ. Enzyme activity inhibition properties of new cellulose nanocrystals from Citrus medica L. pericarp: A perspective of cholesterol lowering.Luminescence202237111836184510.1002/bio.436035946171
    [Google Scholar]
  70. KhursheedR. DuaK. VishwasS. GulatiM. JhaN.K. AldhafeeriG.M. AlanaziF.G. GohB.H. GuptaG. PaudelK.R. HansbroP.M. ChellappanD.K. SinghS.K. Biomedical applications of metallic nanoparticles in cancer: Current status and future perspectives.Biomed. Pharmacother.202215011295110.1016/j.biopha.2022.11295135447546
    [Google Scholar]
  71. KlębowskiB. DepciuchJ. Parlińska-WojtanM. BaranJ. Applications of Noble Metal-Based Nanoparticles in Medicine.Int. J. Mol. Sci.20181912403110.3390/ijms1912403130551592
    [Google Scholar]
  72. CanaparoR. FogliettaF. LimongiT. SerpeL. Biomedical Applications of Reactive Oxygen Species Generation by Metal Nanoparticles.Materials20201415310.3390/ma14010053
    [Google Scholar]
  73. SinghK.R.B. NayakV. SinghJ. SinghA.K. SinghR.P. Potentialities of bioinspired metal and metal oxide nanoparticles in biomedical sciences.RSC Advances20211140247222474610.1039/D1RA04273D35481029
    [Google Scholar]
  74. LiY.F. ChenC. Fate and toxicity of metallic and metal-containing nanoparticles for biomedical applications.Small20117212965298010.1002/smll.20110105921932238
    [Google Scholar]
  75. MurthyS. EffiongP. FeiC.C. Metal oxide nanoparticles in biomedical applications.Metal Oxide Powder Technologies. Al-DouriY. Elsevier202023325110.1016/B978‑0‑12‑817505‑7.00011‑7
    [Google Scholar]
  76. MukherjeeS. DasS. NuthiS. PatraC.R. Biocompatible nickel-prussian blue@silver nanocomposites show potent antibacterial activities.Future Sci. OA201734FSO23310.4155/fsoa‑2017‑004829134120
    [Google Scholar]
  77. RaoB.R. KotcherlakotaR. NethiS.K. PuvvadaN. SreedharB. ChaudhuriA. PatraC.R. Ag2 [Fe (CN) 5NO] nanoparticles exhibit antibacterial activity and wound healing properties.ACS Biomater. Sci. Eng.2018493434344910.1021/acsbiomaterials.8b0075933435077
    [Google Scholar]
  78. DasS. SinghS. ChigurupatiS. MughalM. KumarA. PatraC. OommenS. VlahakisN. MukhopadhyayD. SelfW. Cerium oxide nanoparticles can induce pro-angiogenesis and facilitate wound healing.Wound Repair and Regeneration2012202A20A20
    [Google Scholar]
  79. RaoB.R. KumarR. HaqueS. KumarJ.M. RaoT.N. KothapalliR.V.S.N. PatraC.R. Ag2 [fe (cn) 5no]-fabricated hydrophobic cotton as a potential wound healing dressing: An in vivo approach.ACS Appl. Mater. Interfaces2021139106891070410.1021/acsami.0c1990433621045
    [Google Scholar]
  80. HaqueS. KotcherlakotaR. BhamidipatiP. MuralidharanK. SreedharB. AmanchyR. PatraC.R. Smartly engineered casein manganese oxide nanobiomaterials and its potential therapeutic angiogenesis applications for wound healing and limb ischemia.Adv. Ther202369230014210.1002/adtp.202300142
    [Google Scholar]
  81. KotcherlakotaR. VydiamK. Jeyalakshmi SrinivasanD. MukherjeeS. RoyA. KunchaM. RaoT.N. SistlaR. GopalV. PatraC.R. Restoration of p53 function in ovarian cancer mediated by gold nanoparticle-based egfr targeted gene delivery system.ACS Biomater. Sci. Eng.2019573631364410.1021/acsbiomaterials.9b0000633405744
    [Google Scholar]
  82. AsifK. AdeelM. RahmanM.M. SfrisoA.A. BartolettiM. CanzonieriV. RizzolioF. CaligiuriI. Silver nitroprusside as an efficient chemodynamic therapeutic agent and a peroxynitrite nanogenerator for targeted cancer therapies.J. Adv. Res.202336958586
    [Google Scholar]
  83. BaiD.P. ZhangX.F. ZhangG.L. HuangY.F. GurunathanS. Zinc oxide nanoparticles induce apoptosis and autophagy in human ovarian cancer cells.Int. J. Nanomedicine2017126521653510.2147/IJN.S14007128919752
    [Google Scholar]
  84. ZhangM. YueH. HuangX. WangJ. LiZ. DengX. Novel Platinum Nanoclusters Activate PI3K/AKT/mTOR Signaling Pathway-Mediated Autophagy for Cisplatin-Resistant Ovarian Cancer Therapy.ACS Appl. Mater. Interfaces20221443485024851410.1021/acsami.2c1514336261925
    [Google Scholar]
  85. ElahiN. KamaliM. BaghersadM.H. Recent biomedical applications of gold nanoparticles: A review.Talanta201818453755610.1016/j.talanta.2018.02.08829674080
    [Google Scholar]
  86. MikhailovaE.O. Gold Nanoparticles: Biosynthesis and Potential of Biomedical Application.J. Funct. Biomater.20211247010.3390/jfb1204007034940549
    [Google Scholar]
  87. VersianiA.F. AndradeL.M. MartinsE.M.N. ScalzoS. GeraldoJ.M. ChavesC.R. FerreiraD.C. LadeiraM. GuatimosimS. LadeiraL.O. da FonsecaF.G. Gold nanoparticles and their applications in biomedicine.Future Virol.201611429330910.2217/fvl‑2015‑0010
    [Google Scholar]
  88. CabuzuD. CirjaA. PuiuR. GrumezescuA. Biomedical applications of gold nanoparticles.Curr. Top. Med. Chem.201515161605161310.2174/156802661566615041414475025877087
    [Google Scholar]
  89. PatraC.R. BhattacharyaR. MukherjeeP. Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer.J. Mater. Chem.201020354755410.1039/B913224D20436942
    [Google Scholar]
  90. KumarD. MutrejaI. ChitcholtanK. SykesP. Cytotoxicity and cellular uptake of different sized gold nanoparticles in ovarian cancer cells.Nanotechnology2017284747510110.1088/1361‑6528/aa935e29027909
    [Google Scholar]
  91. JosephD. TyagiN. GeckelerC. E GeckelerK. Protein-coated pH-responsive gold nanoparticles: Microwave-assisted synthesis and surface charge-dependent anticancer activity.Beilstein J. Nanotechnol.2014511452146210.3762/bjnano.5.15825247128
    [Google Scholar]
  92. XiongX. ArvizoR.R. SahaS. RobertsonD.J. McMeekinS. BhattacharyaR. MukherjeeP. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles.Oncotarget20145156453646510.18632/oncotarget.220325071019
    [Google Scholar]
  93. AliM.R.K. WuY. GhoshD. DoB.H. ChenK. DawsonM.R. FangN. SulchekT.A. El-SayedM.A. Nuclear Membrane-Targeted Gold Nanoparticles Inhibit Cancer Cell Migration and Invasion.ACS Nano20171143716372610.1021/acsnano.6b0834528333438
    [Google Scholar]
  94. MaityR. ChatterjeeM. BanerjeeA. DasA. MishraR. MazumderS. ChandaN. Gold nanoparticle-assisted enhancement in the anti-cancer properties of theaflavin against human ovarian cancer cells.Mater. Sci. Eng. C201910410990910.1016/j.msec.2019.10990931499983
    [Google Scholar]
  95. Al-ShammariA.M. Al-SaadiH. Al-ShammariS.M. JabirM.S. Galangin enhances gold nanoparticles as anti-tumor agents against ovarian cancer cells.AIP Conf. Proc.20202213102020610.1063/5.0000162
    [Google Scholar]
  96. AslS.S. TafviziF. NoorbazarganH. Biogenic synthesis of gold nanoparticles using Satureja rechingeri Jamzad: a potential anticancer agent against cisplatin-resistant A2780CP ovarian cancer cells.Environ. Sci. Pollut. Res. Int.2022308201682018410.1007/s11356‑022‑23507‑636251187
    [Google Scholar]
  97. Rezaie AmaleF. FerdowsianS. HajrasoulihaS. KazempoorR. MirzaieA. Sedigh DakkaliM. AkbarzadehI. Mohammadmahdi MeybodiS. MirghafouriM. Gold nanoparticles loaded into niosomes: A novel approach for enhanced antitumor activity against human ovarian cancer.Adv. Powder Technol.202132124711472210.1016/j.apt.2021.10.019
    [Google Scholar]
  98. GurunathanS. LeeK.J. KalishwaralalK. SheikpranbabuS. VaidyanathanR. EomS.H. Antiangiogenic properties of silver nanoparticles.Biomaterials200930316341635010.1016/j.biomaterials.2009.08.00819698986
    [Google Scholar]
  99. YinM. XuX. HanH. DaiJ. SunR. YangL. XieJ. WangY. Preparation of triangular silver nanoparticles and their biological effects in the treatment of ovarian cancer.J. Ovarian Res.202215112110.1186/s13048‑022‑01056‑336411490
    [Google Scholar]
  100. CarlsonC. HussainS.M. SchrandA.M.K. Braydich-StolleL.K. HessK.L. JonesR.L. SchlagerJ.J. Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species.J. Phys. Chem. B200811243136081361910.1021/jp712087m18831567
    [Google Scholar]
  101. AhmadJ. MemonA.G. ShaikhA.A. IsmailT. GiwaA.S. MahmoodA. Insight into single-element nobel metal anisotropic silver nanoparticle shape-dependent selective ROS generation and quantification.RSC Advances202111148314832210.1039/D0RA10616J35423338
    [Google Scholar]
  102. YuanY.-G. PengQ.-L. GurunathanS. Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment.Int. J. Nanomedicine201712null6487650210.2147/IJN.S135482
    [Google Scholar]
  103. FahrenholtzC.D. SwannerJ. Ramirez-PerezM. SinghR.N. Heterogeneous Responses of Ovarian Cancer Cells to Silver Nanoparticles as a Single Agent and in Combination with Cisplatin.J. Nanomater.2017201711110.1155/2017/510748530034459
    [Google Scholar]
  104. ZhangX.-F. GurunathanS. Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy.Int. J. Nanomedicine201611null3655367510.2147/IJN.S111279
    [Google Scholar]
  105. ZhangX.F. HuangF.H. ZhangG.L. BaiD.P. MassimoD.F. HuangY.F. GurunathanS. Novel biomolecule lycopene-reduced graphene oxide-silver nanoparticle enhances apoptotic potential of trichostatin A in human ovarian cancer cells (SKOV3).Int. J. Nanomedicine2017127551757510.2147/IJN.S14416129075115
    [Google Scholar]
  106. LavudiK. HarikaV. S. KokkantiR. R. PatchigollaS. SinhaA. PatnaikS. PenchalaneniJ. 2-Dimensional in vitro culture assessment of ovarian cancer cell line using cost effective silver nanoparticles from Macrotyloma uniflorum seed extractsFront Bioeng Biotechnol20221097884610.3389/fbioe.2022.978846
    [Google Scholar]
  107. LuoD. ChinnathambiA. AlahmadiT.A. PrabakaranD.S. ZhangG. Preparation, characterization and investigation of the anti human ovarian cancer of silver nanoparticles green-formulated by Salvia officinalis leaf aqueous extract.Arch. Med. Sci.202210.5114/aoms/145111
    [Google Scholar]
  108. AboelmaatiM.G. Abdel GaberS.A. SolimanW.E. ElkhatibW.F. AbdelhameedA.M. SahyonH.A. El-KemaryM. Biogenic and biocompatible silver nanoparticles for an apoptotic anti-ovarian activity and as polydopamine-functionalized antibiotic carrier for an augmented antibiofilm activity.Colloids Surf. B Biointerfaces202120611193510.1016/j.colsurfb.2021.11193534252691
    [Google Scholar]
  109. ZhangJ. DingH. ZhangF. XuY. LiangW. HuangL. New trends in diagnosing and treating ovarian cancer using nanotechnology.Front. Bioeng. Biotechnol.202311116098510.3389/fbioe.2023.116098537082219
    [Google Scholar]
  110. AbedA. DerakhshanM. KarimiM. ShiraziniaM. Mahjoubin-TehranM. HomayonfalM. HamblinM.R. MirzaeiS.A. SoleimanpourH. DehghaniS. DehkordiF.F. MirzaeiH. Platinum Nanoparticles in Biomedicine: Preparation, Anti-Cancer Activity, and Drug Delivery Vehicles.Front. Pharmacol.20221379780410.3389/fphar.2022.79780435281900
    [Google Scholar]
  111. JayawardhanaA.M.D.S. QiuZ. KempfS. WangH. MiterkoM. BowersD.J. ZhengY.R. Dual-action organoplatinum polymeric nanoparticles overcoming drug resistance in ovarian cancer.Dalton Trans.20194833124511245810.1039/C9DT01683J31353381
    [Google Scholar]
  112. AswadD. S. QoqajI. Platinum nanoparticles in photothermal therapy of cancer cells.UCPH NanoScience - a student research journal202410
    [Google Scholar]
  113. AliN.H. MohammedA.M. Biosynthesis and characterization of platinum nanoparticles using Iraqi Zahidi dates and evaluation of their biological applications.Biotechnol. Rep202130e0063510.1016/j.btre.2021.e0063534094893
    [Google Scholar]
  114. BendaleY. BendaleV. PaulS. Evaluation of cytotoxic activity of platinum nanoparticles against normal and cancer cells and its anticancer potential through induction of apoptosis.Integr. Med. Res.20176214114810.1016/j.imr.2017.01.00628664137
    [Google Scholar]
  115. ZhangY. XiaM. ZhouZ. HuX. WangJ. ZhangM. LiY. SunL. ChenF. YuH. p53 Promoted Ferroptosis in Ovarian Cancer Cells Treated with Human Serum Incubated-Superparamagnetic Iron Oxides.Int. J.Nanomedicine202116null28329610.2147/IJN.S282489
    [Google Scholar]
  116. BasuliD. TesfayL. DengZ. PaulB. YamamotoY. NingG. XianW. McKeonF. LynchM. CrumC.P. HegdeP. BrewerM. WangX. MillerL.D. DymentN. TortiF.M. TortiS.V. Iron addiction: A novel therapeutic target in ovarian cancer.Oncogene201736294089409910.1038/onc.2017.1128319068
    [Google Scholar]
  117. RamalingamV. HarshavardhanM. Dinesh KumarS. Malathi deviS. Wet chemical mediated hematite α-Fe2O3 nanoparticles synthesis: Preparation, characterization and anticancer activity against human metastatic ovarian cancer.J. Alloys Compd.202083415511810.1016/j.jallcom.2020.155118
    [Google Scholar]
  118. TanG. LiW. ChengJ. WangZ. WeiS. JinY. GuoC. QuF. Magnetic iron oxide modified pyropheophorbide-a fluorescence nanoparticles as photosensitizers for photodynamic therapy against ovarian cancer (SKOV-3) cells.Photochem. Photobiol. Sci.201615121567157810.1039/c6pp00340k27872929
    [Google Scholar]
  119. JabirM.S. NayefU.M. AbdulkadhimW.K. SulaimanG.M. Supermagnetic Fe 3 O 4 -PEG nanoparticles combined with NIR laser and alternating magnetic field as potent anti-cancer agent against human ovarian cancer cells.Mater. Res. Express201961111541210.1088/2053‑1591/ab50a0
    [Google Scholar]
  120. EspinosaA. Di CoratoR. Kolosnjaj-TabiJ. FlaudP. PellegrinoT. WilhelmC. Duality of iron oxide nanoparticles in cancer therapy: amplification of heating efficiency by magnetic hyperthermia and photothermal bimodal treatment.ACS Nano20161022436244610.1021/acsnano.5b0724926766814
    [Google Scholar]
  121. TangD. ChenX. KroemerG. Cuproptosis: a copper-triggered modality of mitochondrial cell death.Cell Res.202232541741810.1038/s41422‑022‑00653‑735354936
    [Google Scholar]
  122. HouP. KuangH. DengW. LeiY. Immobilized copper nanoparticles on biodegradable magnetic starch composite: investigation of its ovarian cancer, cytotoxicity, and antioxidant effects.J. Exp. Nanosci.202217149650810.1080/17458080.2022.2110241
    [Google Scholar]
  123. HeH. AltomareD. OzerU. XuH. CreekK. ChenH. XuP. Cancer cell-selective killing polymer/copper combination.Biomater. Sci20164111512010.1039/C5BM00325C
    [Google Scholar]
  124. HanW. LiuX. WangL. ZhouX. Engineering of lipid microbubbles-coated copper and selenium nanoparticles: Ultrasound-stimulated radiation of anticancer activity ian human ovarian cancer cells.Process Biochem.20209811312110.1016/j.procbio.2020.07.013
    [Google Scholar]
  125. DouL. ZhangX. ZangenehM.M. ZhangY. Efficient biogenesis of Cu2O nanoparticles using extract of Camellia sinensis leaf: Evaluation of catalytic, cytotoxicity, antioxidant, and anti-human ovarian cancer properties.Bioorg. Chem.202110610446810.1016/j.bioorg.2020.10446833229117
    [Google Scholar]
  126. ShahriaryS. TafviziF. KhodarahmiP. ShaabanzadehM. Phyto-mediated synthesis of CuO nanoparticles using aqueous leaf extract of Artemisia deserti and their anticancer effects on A2780-CP cisplatin-resistant ovarian cancer cells.Biomass Convers. Biorefin.20241422263227910.1007/s13399‑022‑02436‑x
    [Google Scholar]
  127. AboeitaN.M. FahmyS.A. El-SayedM.M.H. AzzazyH.M.E.S. ShoeibT. Enhanced Anticancer Activity of Nedaplatin Loaded onto Copper Nanoparticles Synthesized Using Red Algae.Pharmaceutics202214241810.3390/pharmaceutics1402041835214150
    [Google Scholar]
  128. SirelkhatimA. MahmudS. SeeniA. KausN.H.M. AnnL.C. BakhoriS.K.M. HasanH. MohamadD. Review on Zinc Oxide Nanoparticles: Antibacterial Activity and Toxicity Mechanism.Nano-Micro Lett.20157321924210.1007/s40820‑015‑0040‑x30464967
    [Google Scholar]
  129. SahooR.K. RaniS. KumarV. GuptaU. 17 Zinc oxide nanoparticles for bioimaging and drug delivery.Nanostructured Zinc Oxide. AwasthiK. Elsevier202148350910.1016/B978‑0‑12‑818900‑9.00021‑8
    [Google Scholar]
  130. GuW. YangC. Zinc oxide nanoparticles inhibit malignant progression and chemotherapy resistance of ovarian cancer cells by activating endoplasmic reticulum stress and promoting autophagy.Exp. Ther. Med.202326550810.3892/etm.2023.1220737840563
    [Google Scholar]
  131. HadiA.J. NayefU.M. MutlakF.A.H. JabirM.S. Laser-Ablated Zinc Oxide Nanoparticles and Evaluation of Their Antibacterial and Anticancer Activity Against an Ovarian Cancer Cell Line: In Vitro Study.Plasmonics20231862091210110.1007/s11468‑023‑01933‑7
    [Google Scholar]
  132. PadmanabhanA. KaushikM. NiranjanR. RichardsJ.S. EbrightB. VenkatasubbuG.D. Zinc oxide nanoparticles induce oxidative and proteotoxic stress in ovarian cancer cells and trigger apoptosis independent of p53-mutation status.Appl. Surf. Sci.201948780781810.1016/j.apsusc.2019.05.09932042215
    [Google Scholar]
  133. AlipourS. Gholizadeh-Ghaleh AzizS. BabaeiG. AbolhasaniS. Alantolactone and ZnO nanoparticles induce apoptosis activity of cisplatin in an ovarian cancer cell line (SKOV3).Res. Pharm. Sci.202217329430410.4103/1735‑5362.34308335531132
    [Google Scholar]
  134. LiJ. HuZ. ZhuJ. LinX. GaoX. LvG. Antitumor Effects of Pegylated Zinc Protoporphyrin-Mediated Sonodynamic Therapy in Ovarian Cancer.Pharmaceutics2023159227510.3390/pharmaceutics1509227537765244
    [Google Scholar]
  135. MousaA.B. MoawadR. AbdallahY. Abdel-RasheedM. ZaherA.M.A. Zinc Oxide Nanoparticles Promise Anticancer and Antibacterial Activity in Ovarian Cancer.Pharm. Res.202340102281229010.1007/s11095‑023‑03505‑037016170
    [Google Scholar]
  136. IravaniS. VarmaR.S. Sustainable synthesis of cobalt and cobalt oxide nanoparticles and their catalytic and biomedical applications.Green Chem.20202292643266110.1039/D0GC00885K
    [Google Scholar]
  137. AnsariS.M. BhorR.D. PaiK.R. SenD. MazumderS. GhoshK. KolekarY.D. RamanaC.V. Cobalt nanoparticles for biomedical applications: Facile synthesis, physiochemical characterization, cytotoxicity behavior and biocompatibility.Appl. Surf. Sci.201741417118710.1016/j.apsusc.2017.03.002
    [Google Scholar]
  138. GornatiR. PedrettiE. RossiF. CappelliniF. ZanellaM. OlivatoI. SabbioniE. BernardiniG. Zerovalent Fe, Co and Ni nanoparticle toxicity evaluated on SKOV-3 and U87 cell lines.J. Appl. Toxicol.201636338539310.1002/jat.322026378417
    [Google Scholar]
  139. PašukonienėV. MlynskaA. SteponkienėS. PoderysV. MatulionytėM. KarabanovasV. StatkutėU. PurvinienėR. KraśkoJ.A. JagminasA. KurtinaitienėM. StriogaM. RotomskisR. Accumulation and biological effects of cobalt ferrite nanoparticles in human pancreatic and ovarian cancer cells.Medicina201450423724410.1016/j.medici.2014.09.00925458961
    [Google Scholar]
  140. AdeelM. ParisiS. MauceriM. AsifK. BartolettiM. PuglisiF. CaligiuriI. RahmanM.M. CanzonieriV. RizzolioF. Self-Therapeutic Cobalt Hydroxide Nanosheets (Co(OH) 2 NS) for Ovarian Cancer Therapy.ACS Omega2021643286112861910.1021/acsomega.1c0301034746556
    [Google Scholar]
  141. ToubhansB. GazzeS.A. BissardonC. BohicS. GourlanA.T. GonzalezD. CharletL. ConlanR.S. FrancisL.W. Selenium nanoparticles trigger alterations in ovarian cancer cell biomechanics.Nanomedicine20202910225810.1016/j.nano.2020.10225832615338
    [Google Scholar]
  142. SonkusreP. CameotraS.S. Biogenic selenium nanoparticles induce ROS-mediated necroptosis in PC-3 cancer cells through TNF activation.J. Nanobiotechnology20171514310.1186/s12951‑017‑0276‑328592284
    [Google Scholar]
  143. HuangG. LiuZ. HeL. LukK.H. CheungS.T. WongK.H. ChenT. Autophagy is an important action mode for functionalized selenium nanoparticles to exhibit anti-colorectal cancer activity.Biomater. Sci.2018692508251710.1039/C8BM00670A30091749
    [Google Scholar]
  144. ChenT. WongY.S. Selenocystine induces reactive oxygen species–mediated apoptosis in human cancer cells.Biomed. Pharmacother.200963210511310.1016/j.biopha.2008.03.00918511231
    [Google Scholar]
  145. Nasrolahi ShiraziA. TiwariR.K. OhD. SullivanB. KumarA. BeniY.A. ParangK. Cyclic peptide-selenium nanoparticles as drug transporters.Mol. Pharm.201411103631364110.1021/mp500364a25184366
    [Google Scholar]
  146. BidkarA.P. SanpuiP. GhoshS.S. Efficient induction of apoptosis in cancer cells by paclitaxel-loaded selenium nanoparticles.Nanomedicine201712212641265110.2217/nnm‑2017‑018929043926
    [Google Scholar]
  147. LiX. ZhangY. ChaiX. ZhouS. ZhangH. HeJ. ZhouR. CaiL. ChenL. TaoG. Overexpression of MEF2D contributes to oncogenic malignancy and chemotherapeutic resistance in ovarian carcinoma.Am. J. Cancer Res.20199588790531218100
    [Google Scholar]
  148. WangC. XiaY. HuoS. ShouD. MeiQ. TangW. LiY. LiuH. ZhouY. ZhuB. Silencing of MEF2D by siRNA Loaded Selenium Nanoparticles for Ovarian Cancer Therapy.Int. J. Nanomedicine202015null9759977010.2147/IJN.S270441
    [Google Scholar]
  149. SantosI. RamosC. MendesC. SequeiraC.O. ToméC.S. FernandesD.G.H. MotaP. PiresR.F. UrsoD. HipólitoA. AntunesA.M.M. VicenteJ.B. PereiraS.A. BonifácioV.D.B. NunesS.C. SerpaJ. Targeting Glutathione and Cystathionine β-Synthase in Ovarian Cancer Treatment by Selenium–Chrysin Polyurea Dendrimer Nanoformulation.Nutrients20191110252310.3390/nu1110252331635026
    [Google Scholar]
  150. AmiriH. HashemyS.I. SabouriZ. JavidH. DarroudiM. Green synthesized selenium nanoparticles for ovarian cancer cell apoptosis.Res. Chem. Intermed.20214762539255610.1007/s11164‑021‑04424‑8
    [Google Scholar]
  151. PhanT.T.V. HuynhT.C. ManivasaganP. MondalS. OhJ. An up-to-date review on biomedical applications of palladium nanoparticles.Nanomaterials20191016610.3390/nano1001006631892149
    [Google Scholar]
  152. GurunathanS. KimE. HanJ. ParkJ. KimJ.H. Green Chemistry Approach for Synthesis of Effective Anticancer Palladium Nanoparticles.Molecules20152012224762249810.3390/molecules20121986026694334
    [Google Scholar]
  153. GurunathanS. QasimM. ParkC.H. Arsalan IqbalM. YooH. HwangJ.H. UhmS.J. SongH. ParkC. ChoiY. KimJ.H. HongK. Cytotoxicity and Transcriptomic Analyses of Biogenic Palladium Nanoparticles in Human Ovarian Cancer Cells (SKOV3).Nanomaterials20199578710.3390/nano905078731121951
    [Google Scholar]
  154. GiriS. KarakotiA. GrahamR.P. MaguireJ.L. ReillyC.M. SealS. RattanR. ShridharV. Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer.PLoS One201381e5457810.1371/journal.pone.005457823382918
    [Google Scholar]
  155. AshnaM. Es-haghiA. SoltaniM. Apoptotic Genes’ Expression in an Ovarian Cancer Cell Line (A2780) Exposed to Green Synthesized Cerium Oxide Nanoemulsion.International Journal of Basic Science in Medicine202162515610.34172/ijbsm.2021.09
    [Google Scholar]
  156. VassieJ.A. WhitelockJ.M. LordM.S. Endocytosis of cerium oxide nanoparticles and modulation of reactive oxygen species in human ovarian and colon cancer cells.Acta Biomater.20175012714110.1016/j.actbio.2016.12.01027940194
    [Google Scholar]
  157. HijazM. DasS. MertI. GuptaA. Al-WahabZ. TebbeC. DarS. ChhinaJ. GiriS. MunkarahA. SealS. RattanR. Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer.BMC Cancer201616122010.1186/s12885‑016‑2206‑426979107
    [Google Scholar]
  158. HannaD.H.R. R SaadG. Induction of mitochondria mediated apoptosis in human ovarian cancer cells by folic acid coated tin oxide nanoparticles.PLoS One20211610e025811510.1371/journal.pone.025811534597348
    [Google Scholar]
  159. YangY. ZhangM. SongH. YuC. Silica-Based Nanoparticles for Biomedical Applications: From Nanocarriers to Biomodulators.Acc. Chem. Res.20205381545155610.1021/acs.accounts.0c0028032667182
    [Google Scholar]
  160. HudsonS.P. PaderaR.F. LangerR. KohaneD.S. The biocompatibility of mesoporous silicates.Biomaterials200829304045405510.1016/j.biomaterials.2008.07.00718675454
    [Google Scholar]
  161. BaezaA. ManzanoM. ColillaM. Vallet-RegíM. Recent advances in mesoporous silica nanoparticles for antitumor therapy: our contribution.Biomater. Sci20164580381310.1039/C6BM00039H
    [Google Scholar]
  162. Sanchez-SalcedoS. Vallet-RegíM. ShahinS.A. GlackinC.A. ZinkJ.I. Mesoporous core-shell silica nanoparticles with anti-fouling properties for ovarian cancer therapy.Chem. Eng. J.201834011412410.1016/j.cej.2017.12.116
    [Google Scholar]
  163. AlizadehL. AlizadehE. ZarebkohanA. AhmadiE. Rahmati-YamchiM. SalehiR. AS1411 aptamer-functionalized chitosan-silica nanoparticles for targeted delivery of epigallocatechin gallate to the SKOV-3 ovarian cancer cell lines.J. Nanopart. Res.2020221510.1007/s11051‑019‑4735‑7
    [Google Scholar]
  164. TorabiM. AghanejadA. SavadiP. BarzegariA. OmidiY. BararJ. Fabrication of mesoporous silica nanoparticles for targeted delivery of sunitinib to ovarian cancer cells.Bioimpacts202313325526710.34172/bi.2023.2529837431477
    [Google Scholar]
  165. KhanA.U. KhanM. ChoM.H. KhanM.M. Selected nanotechnologies and nanostructures for drug delivery, nanomedicine and cure.Bioprocess Biosyst. Eng.20204381339135710.1007/s00449‑020‑02330‑832193755
    [Google Scholar]
  166. GuptaV. MohapatraS. MishraH. FarooqU. KumarK. AnsariM. AldawsariM. AlalaiweA. MirzaM. IqbalZ. Nanotechnology in Cosmetics and Cosmeceuticals—A Review of Latest Advancements.Gels20228317310.3390/gels803017335323286
    [Google Scholar]
  167. MazayenZ.M. GhoneimA.M. ElbatanonyR.S. BasaliousE.B. BendasE.R. Pharmaceutical nanotechnology: from the bench to the market.Fut. J. Pharm. Sci.2022811210.1186/s43094‑022‑00400‑035071609
    [Google Scholar]
  168. HaqueS. TripathyS. PatraC. R. Manganese-based advanced nanoparticles for biomedical applications: future opportunity and challenges.Nanoscale20211339164051642610.1039/D1NR04964J
    [Google Scholar]
  169. García-TorraV. CanoA. EspinaM. EttchetoM. CaminsA. BarrosoE. Vazquez-CarreraM. GarcíaM.L. Sánchez-LópezE. SoutoE.B. State of the Art on Toxicological Mechanisms of Metal and Metal Oxide Nanoparticles and Strategies to Reduce Toxicological Risks.Toxics20219819510.3390/toxics908019534437513
    [Google Scholar]
  170. SchrandA.M. RahmanM.F. HussainS.M. SchlagerJ.J. SmithD.A. SyedA.F. Metal-based nanoparticles and their toxicity assessment.Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.20102554456810.1002/wnan.10320681021
    [Google Scholar]
  171. MediciS. PeanaM. PelucelliA. ZorodduM.A. An updated overview on metal nanoparticles toxicity.Semin. Cancer Biol.202176172610.1016/j.semcancer.2021.06.02034182143
    [Google Scholar]
  172. HaqueS. TripathyS. ChandraY. MuralidharanK. PatraC.R. Toxicity study of pro-angiogenic casein manganese oxide nanoparticles: an in vitro and in vivo approach.Nanotoxicology2023171060462710.1080/17435390.2023.229178838105710
    [Google Scholar]
  173. PujaltéI. PassagneI. DaculsiR. de PortalC. Ohayon-CourtèsC. L'AzouB. Cytotoxic effects and cellular oxidative mechanisms of metallic nanoparticles on renal tubular cells: impact of particle solubility.Toxicol. Res20154240942210.1039/C4TX00184B
    [Google Scholar]
  174. SosaV. MolinéT. SomozaR. PaciucciR. KondohH. LLeonartM.E. Oxidative stress and cancer: An overview.Ageing Res. Rev.201312137639010.1016/j.arr.2012.10.00423123177
    [Google Scholar]
  175. LiY. YangJ. SunX. Reactive oxygen species-based nanomaterials for cancer therapy.Front Chem.2021965058710.3389/fchem.2021.65058733968899
    [Google Scholar]
  176. Turki JalilA. AbdulhadiM.A. Al-AmeerL.R. WasheelO.F. AbdulameerS.J. MerzaM.S. AbosaoodaM. MahdiA.A. Free radical based nano cancer therapy.J. Drug Deliv. Sci. Technol.20238710480310.1016/j.jddst.2023.104803
    [Google Scholar]
  177. LingP. YangP. ZhangQ. TangC. GaoX. WangL. XuW. pH-Responsive Multifunctional Nanoplatforms with Reactive Oxygen Species-Controlled Release of CO for Enhanced Oncotherapy.ACS Appl. Bio Mater.20236125708571510.1021/acsabm.3c0083437990995
    [Google Scholar]
  178. SubhanM.A. YalamartyS.S.K. FilipczakN. ParveenF. TorchilinV.P. Recent advances in tumor targeting via EPR effect for cancer treatment.J. Pers. Med.202111657110.3390/jpm1106057134207137
    [Google Scholar]
  179. DasS. TripathyS. SreedharB. MukherjeeS. PatraC.R. Design of Lysozyme-Templated Biocompatible Fluorescent Nanocomposites and Their Potential Applications for Cell Imaging, Hydrogen Peroxide Sensing, and Cancer Therapy.Adv. Ther202366220029310.1002/adtp.202200293
    [Google Scholar]
  180. BaruiA.K. BolluV.S. LondheS. DeshpandeS.S. DasS. NethiS.K. AlabbasiM.M.A. KunchaM. KumarJ.M. SistlaR. MisraS. PatraC.R. Toxicological evaluation of therapeutically active zinc oxide nanoflowers in pre-clinical mouse model.NanoImpact20233110047910.1016/j.impact.2023.10047937572937
    [Google Scholar]
  181. MukherjeeS. BolluV.S. RoyA. NethiS.K. MadhusudanaK. KumarJ.M. SistlaR. PatraC.R. Acute toxicity, biodistribution, and pharmacokinetics studies of pegylated platinum nanoparticles in mouse model.Adv. NanoBiomed Res.202117200008210.1002/anbr.202000082
    [Google Scholar]
  182. BolluV.S. BathiniT. BaruiA.K. RoyA. RagiN.C. MalothS. SripadiP. SreedharB. NagababuP. PatraC.R. Design of DNA-intercalators based copper(II) complexes, investigation of their potential anti-cancer activity and sub-chronic toxicity.Mater. Sci. Eng. C201910511007910.1016/j.msec.2019.11007931546406
    [Google Scholar]
  183. TripathyS. HaqueS. LondheS. DasS. NorbertC.C. ChandraY. SreedharB. PatraC.R. ROS mediated Cu[Fe(CN)5NO] nanoparticles for triple negative breast cancer: A detailed study in preclinical mouse model.Biomaterials Advances202416021383210.1016/j.bioadv.2024.21383238547763
    [Google Scholar]
  184. ChandrakalaV. ArunaV. AngajalaG. Review on metal nanoparticles as nanocarriers: current challenges and perspectives in drug delivery systems.Emergent Materials2022561593161510.1007/s42247‑021‑00335‑x35005431
    [Google Scholar]
  185. RoyA. BasuthakurP. HaqueS. PatraC.R. Silver-based nanoparticles for antibacterial activity.Microbial Interactions at Nanobiotechnology Interfaces: Molecular Mechanisms and ApplicationsWiley Online Library202110.1002/9781119617181.ch8
    [Google Scholar]
/content/journals/cis/10.2174/012210299X310916240801111606
Loading
/content/journals/cis/10.2174/012210299X310916240801111606
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test